The Company expects first quarter revenue of $1.25 million reflecting a full quarter of revenue contribution from the Kenkoderm acquisition but excluding a $176,000 non-refundable deposit from Abbvie for their first order.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXGL:
- NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
- NexGel reschedules Q4, 2023 results conference call
- NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th
- Nexgel, Inc. (NXGL) Q4 Earnings Cheat Sheet
- NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
